EGFR and non-small cell lung carcinoma: Based on the success of a number of pivotal trials in selected EGFR mutation–positive patients (Mok et al., 2009; Maemondo et al., 2010; Mitsudomi et al., 2010; Zhou et al., 2011; Rosell et al., 2012; Sequist et al., 2013; Wu et al., 2014), gefitinib, erlotinib, and afatinib are now recommended by the NCCN for first-line treatment for patients with advanced or metastatic EGFR mutation–positive (exon 19 deletions or exon 21 [L858R] substitution mutations) NSCLC (Lindeman et al., 2013; NCCN, 2016; AstraZeneca, 2015a; Genentech, 2015; Boehringer Ingelheim Pharmaceuticals, 2014).